1983
Cuba held its First Cuban Seminar on Interferon, established the Cuban Society for Interferon Research, and began the National Program for the treatment of laryngeal papillomatosis with interferon. In addition, the development and production of monoclonal antibodies was incorporated, including those used for the immunoaffinity purification of interferon and the hepatitis B vaccine. Interferon ß was the first molecule expressed in Cuba in a heterologous host and the first number of the magazine Interferón y Biotecnología, in response to the need to exchange information between the nascent Cuban biotechnology industry and researchers from other, especially Ibero-American countries.